clinical trial · NCT03055611
A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B
Swedish Orphan Biovitrum·—·completed·n = 201
Haemophilia AHaemophilia BELOCTAALPROLIX
brief summary
Elocta (rFVIIIFc) and Alprolix (rFIXFc) are recombinant extended half-life coagulation factor products. The purpose of this non-interventional study is to describe the real-world usage and effectiveness of Elocta and Alprolix in the prophylactic treatment of haemophilia A and B.
started
May 9, 2017
primary completion
Apr 19, 2022
completion
Apr 19, 2022
last updated
Oct 2, 2024
official title
A 24-month Prospective, Non-interventional, Multicentre Study to Evaluate the Real-World Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol